asic fibroblast growth factor (bFGF), which is a potent mitogen that regulates angiogenesis during growth and development, 1 has been successfully used to stimulate cardiac angiogenesis to improve myocardial blood flow through various routes of administration in a variety of animal models of myocardial ischemia. [2] [3] [4] [5] [6] [7] [8] [9] However, the biological effect of bFGF in its free form (free-form bFGF) is limited because of its short half-life in vivo, so we have developed acidic gelatin hydrogel microspheres (AGHM) that enable slow and continuous release of bFGF with a resultant prolonged action. 10 When implanted in rabbit skull defects, bFGF-impregnated AGHM promoted bone regeneration and histological examination revealed that the bFGF-impregnated AGHM resulted in more prolonged and greater retention of osteoblasts in the bone defect than with free-form bFGF. 10 In the present study, we used a canine model to test the hypothesis that bFGF-impregnated AGHM applied to the myocardium adjacent to an occluded coronary artery would promote collateral development. Furthermore, we hypotheJapanese Circulation Journal Vol. 65, May 2001 sized that collateral development would be directed to the area where the bFGF-impregnated microspheres were applied, and that the angiogenic response would not be observed in the normal region despite the bFGF treatment.
sized that collateral development would be directed to the area where the bFGF-impregnated microspheres were applied, and that the angiogenic response would not be observed in the normal region despite the bFGF treatment.
Methods

Preparation of Gelatin Microspheres Incorporating bFGF
AGHM were prepared through glutaraldehyde crosslinking in the dispersed state of a gelatin aqueous solution in the oil phase. 10 Briefly, 10 ml of aqueous solution of acidic gelatin (10 wt%) preheated at 45°C was added dropwise into 375 ml of olive oil while stirring at 450 rpm at 45°C for 10 min to yield a water-in-oil emulsion. The emulsion temperature was decreased to 15°C, followed by further continuous stirring for 30 min to induce spontaneous gelation of the gelatin aqueous solution. After the addition of 100 ml of acetone, the emulsion was further stirred for 1 h. The resulting microspheres were washed with acetone and isopropyl alcohol, centrifuged at 5,000 rpm for 5 min, and dried. The non-crosslinked and dried gelatin microspheres (50 mg) were placed in 0.1 wt% of Tween 80 aqueous solution containing 3 mmol/L of glutaraldehyde (10 ml) and stirred at 4°C for 15 h to facilitate their crosslinking. After collection by centrifugation at 5,000 rpm for 5 min at 4°C, the microspheres were further agitated in 100 ml of 10 mmol/L glycine aqueous solution at 37°C for 1 h to block residual aldehyde groups of unreacted glutaraldehyde. The resulting microspheres were finally washed with distilled The present study examined whether basic fibroblast growth factor (bFGF)-impregnated acidic gelatin hydrogel microspheres (AGHM) would enhance collateral development to the infarct area in dogs with coronary occlusion. Studies were conducted in 28 dogs with a 2-week occlusion of the proximal left anterior descending coronary artery (LAD). The dogs were divided into 3 groups according to treatment: Group A treated with bFGF-impregnated AGHM in the infarct area; Group B with free-form bFGF; Group C with AGHM alone. Coronary angiography (n=15; Group A, 7 dogs; Group B, 5 dogs; Group C, 3 dogs) and a regional myocardial blood flow study (n=13; Group A, 6 dogs; Group B, 4 dogs; Group C, 3 dogs) were repeated at a 2-week interval. Coronary angiography revealed that in Group A, antegrade flow in the LAD distal to the occlusion, which was assessed by Thrombolysis in Myocardial Infarction (TIMI) grade, was significantly increased after treatment. In contrast, in Groups B and C, the treatment did not change the flow grade in the LAD. In Group A, the regional myocardial blood flow in the collateral dependent area was significantly increased after treatment, and the regional myocardial blood flow reserve after adenosine injection was also significantly increased. These measurements remained after treatment in Groups B and C. The immunohistochemical study with factor VIII-related antigen revealed an increase of vascular density in the ischemic region in Group A. Intramyocardial delivery of bFGF-impregnated AGHM, but not free-form bFGF, improves the collateral circulation to the infarct area of a coronary occlusion in dogs. ( water, centrifuged at 5,000 rpm for 5 min, and freeze-dried. The pore of the freeze-dried hydrogels ranged from 20 to 60 m. When calculated from their volume before and after swelling in phosphate-buffered saline solution (PBS, pH7.4) for 24 h at 37°C, the water content of the gelatin microspheres was 95 wt%. To incorporate bFGF into the AGHM, 10 l of the bFGF solution (100 g bFGF) was dropped onto 10 mg of dried glutaraldehyde-crosslinked microspheres, which were left to impregnate for 12 h at 4°C. The bFGF-free, empty gelatin microspheres were prepared similarly, using water without bFGF.
Surgical Preparation
Experiments were performed in 28 adult mongrel dogs (mean body weight, 20.3±0.6 kg). All experiments were conducted in accordance with the guidelines for use and care of laboratory animals of Hirosaki University. The dogs were premedicated with a subcutaneous injection of xylazine (4 mg/kg) and atropine sulfate (0.05 mg/kg), and anesthetized with pentobarbital (25 mg/kg) and pancuronium bromide (0.7 mg/kg). Under anesthesia, the dogs were intubated and ventilated by a fixed-volume, positive-pressure respirator (Igarashi Medical Industry, Japan) with room air supplemented by oxygen. Arterial blood gases were measured and corrected when necessary by adjustments of tidal volume, oxygen concentration and administration of sodium bicarbonate. Blood volume loss resulting from the surgery was supplemented with 6% dextran and/or normal saline.
Using a sterile technique, left thoracotomy was performed at the 5th intercostal space. The left anterior descending coronary artery (LAD) between the branches of the first and second diagonal arteries was dissected and 2 silk sutures were placed for ligation. Transient LAD occlusion for a 3-min period was done twice at an interval of 1 min and then the artery was permanent occluded. The chest was closed and the dogs were allowed to recover. Antibiotics were given subcutaneously for 3 days.
The dogs were divided into 2 study groups: 15 dogs underwent a coronary angiography (CAG) study, and the other 13 underwent a regional myocardial blood flow study.
Coronary Angiography Study (n=15)
Two weeks after the occlusion, the dogs were again anesthetized in the same way as described before, and after filming the baseline angiogram of the left coronary artery, the chest was re-opened and the heart suspended in a pericardial cradle. The 15 dogs were randomly assigned to 3 treatment groups. In 7 dogs (Group A), 10 mg of AGHM containing 100 g of bFGF (AGHM-bFGF) was implanted in the subepicardial layer of 2 sites distal and adjacent to the LAD occlusion site (5 mg of AGHM at each site). Another 10 mg of AGHM-bFGF was implanted in the subepicardial layer of 2 sites adjacent to the proximal left circumflex artery (LCX). The dose of bFGF was determined from previous observations of the effect of bFGF-impregnated AGHM on rabbit skull defects. 10 In another group of 5 dogs (Group B), free-form bFGF without AGHM impregnation (0.2 ml solution containing 100 g of bFGF) was injected into the subepicardial layer of the 2 sites adjacent to the LAD and the LCX, and in the remaining 3 dogs (Group C), AGHM alone was administered in the same way. The dogs were again allowed to recover, and 2 weeks later CAG using a pericutaneous technique was repeated under anesthesia to assess coronary collateral development using the TIMI (Thrombolysis in Myocardial Infarction) flow grade: 11 grade 0 indicates no perfusion, grade 1 = penetration without perfusion, grade 2 = partial perfusion, and grade 3 = complete perfusion.
In all 15 dogs, left ventriculography in the right anterior oblique projection and measurement of left ventricular pressure were performed 2 weeks after the occlusion (ie, just before treatment with AGHM-bFGF or free-form bFGF or AGHM) and 2 weeks after the treatment. Left ventricular ejection fraction (LVEF) and left ventricular end-diastolic pressure (LVEDP) measured before and after treatment and compared.
Regional Myocardial Blood Flow Study (n=13)
Two weeks after the occlusion, the dogs were anesthetized and a regional myocardial blood flow (Qm) study was performed using of non-radioactive colored microspheres. The chest was re-opened, a multihole 7-Fr polyethylene tube was inserted into the center of the left atrium via the left atrial appendage and 2 sets of different colored microspheres were infused before and after intravenous administration of adenosine (2 mg/kg) to measure Qm at baseline and after adenosine injection. Then AGHM-bFGF (Group A, n=6), free-form bFGF (Group B, n=4), or AGHM alone (Group C, n=3) was administered as for the CAG study. The chest was closed and the dogs were allowed to recover. Two weeks later, the chest was re-opened under anesthesia and Qm at baseline and after adenosine injection was again measured using the 2 different colored microspheres. At each experiment, arterial blood was withdrawn from the aorta at a rate of 10 ml/min starting 10 s before microsphere infusion and ending 90 s after the infusion. After these procedures, the heart was resected.
The heart was cut transversely at the midpoint between the LAD occlusion site and the apex with a thickness of approximately 1.0 cm. The right ventricular wall was removed. This slice sample was then divided into 12-16 pieces, each of which weighed approximately 2.0 g (2.14± 0.05 g), with 3-5 of the pieces being from the ischemic region sandwiched by the LAD and the second diagonal branch and the remainder from the non-ischemic region perfused by the LCX. Qm was determined as described previously. 12 Briefly, tissue samples were digested and the microspheres were retrieved by filtration of the digestate. The dye on the microspheres was then digested into solution using dimethylformamide and the photometric absorption of the resulting sample was measured by a diode array spectrophotometer (UV-1200, Shimadzu, Japan). The composite spectrum was then resolved at the peak frequencies into the contributions from the individual colored microspheres using a matrix inversion technique. The number of microspheres in each sample was calculated according to the optical density at the wavelength corresponding to each dye color using standardization curves generated from known quantities of microspheres from the same batch of spheres. Myocardial blood flow reserve was determined by dividing Qm measured after adenosine by Qm at baseline.
Immunohistochemical Study
After completion of the CAG and regional myocardial flow studies, histological specimens were obtained from the LAD region just distal to the ligation site (ie, the ischemic region) and LCX region just distal to the adminis-tration site (the non-ischemic region) of AGHM-bFGF, free bFGF or AGHM. They were stained with factor VIIIrelated antigen based on the SAB method. Vascular density was determined by counting the number of vessels with diameters from 10 to 100 m in the ischemic and nonischemic areas and was expressed as number per unit area.
Data Analysis
All data are shown as mean ± SEM. Comparison of continuous variables between the 2 groups was performed with a 2-tailed t-test and that of discontinuous ones with a chi-square test. The level of significance was p<0.05. Table 1 shows the heart rate and mean arterial blood pressure at the time of the CAG study; there were no differences in either baseline parameter among the 3 groups. Both parameters remained unchanged 2 weeks after treatment in each group. Baseline left coronary angiograms revealed total occlusion of the LAD at the ligation site and either no or limited antegrade flow to the distal segment of the ligation site. Baseline antegrade flow grade was 0 in 4 dogs, and 1 in the remaining 11. Two weeks after treatment, the antegrade flow grade to the distal segment of the ligation site in Group A was 1 in 1 dog, 2 in 3 dogs, and 3 in the remaining 3 dogs (Fig 1, left panel) ; in Group B, it was 0 in 1 dog, 1 in 3 dogs, and 2 in the remaining 1 dog (Fig 1, center panel) ; in Group C, it was 0 in 1 dog and 1 in the remaining 2 dogs (Fig 1, right panel) . The antegrade flow grade after treatment increased significantly in Group A (p=0.016), but not in the other groups. LVEF did not change after treatment with AGHM-bFGF, free-form bFGF or AGHM in either group. In Group A, it was 27.9±1.2% and 31.1±2.3% before and after AGHMbFGF, respectively (p=NS), in Group B, it was 31.7±2.3% and 32.2±1.7% before and after free-form bFGF, respectively (p=NS), and in Group C, the LVEF was 30.9±3.6% and 30.5±2.5% before and after AGHM, respectively (p=NS). The wall motion in the left ventricular anterior segment (ie, the infarcted region) did not change after the treatment. LVEDP did not change after the treatment in either group (Group A: 12.4±1.0 mmHg and 11.5±1.2 mmHg before and after AGHM-bFGF, respectively (p=NS); Group B: 11.2±0.9 mmHg and 10.3±1.2 mmHg before and after free-form bFGF, respectively (p=NS); Group C: 11.0± 1.5 mmHg and 10.8±1.7 mmHg before and after AGHM, respectively (p=NS)). Table 2 shows the heart rate and mean arterial blood pressure for each treatment group before and after adenosine infusion; there were no differences in either parameter measured before adenosine. Both at baseline and 2 weeks after treatment, adenosine infusion resulted in an increase in heart rate (all p<0.05) and a decrease in the mean arterial blood pressure (all p<0.05). Neither heart rate nor arterial blood pressure differed among the 3 groups after adenosine infusion. Fig 3 shows representative examples of each of the 3 groups and the effects of each treatment on transmural Qm measured before (upper panels) and after adenosine infusion (lower panels). Transmural Qm in the ischemic region (anterior segments) increased after AGHM-bFGF treatment (Group A), but was not after free-form bFGF (Group B) or AGHM (Group C). For all study dogs, AGHM-bFGF increased the baseline transmural Qm in the ischemic region from 0.50±0.07 to 0.77±0.06 ml/min·g (p=0.0003), whereas neither free-form bFGF (0.48±0.02 to 0.54±0.03 ml/min·g, p=NS) nor AGHM (0.47±0.04 to 0.44±0.06 ml/min · g, p=NS) affected it (Fig 4, left panel) . Administration of AGHM-bFGF, free-form bFGF or AGHM alone did not change Qm in the non-ischemic region perfused by the LCX (Fig 4, right panel) .
Results
Coronary Angiography Study
Regional Myocardial Blood Flow Study
Similar findings were observed in the transmural Qm measured after adenosine injection. AGHM-bFGF increased Qm in the ischemic region from 0.72±0.08 to 1.37±0.07 ml/min·g (p=0.0003), but neither free-form bFGF (0.71± 0.05 to 0.75±0.02 ml/min·g, p=NS) nor AGHM (0.69±0.08 to 0.66±0.07 ml/min·g, p=NS) affected it.
In the ischemic region, AGHM-bFGF increased myocardial blood flow reserve from 1.41±0.12 to 1.81±0.09 (p=0.031), whereas neither free-form bFGF (1.47±0.12 to 1.40±0.08, p=NS) nor AGHM (1.43±0.15 to 1.51±0.07, p=NS) changed it (Fig 5) . In the non-ischemic region, myocardial flow reserve at baseline and after treatment was 3.02±0.17 and 2.99±0.20, respectively, in Group A, 2.83± 0.23 and 2.87±0.13, respectively, in Group B, and 3.26± 0.12 and 3.18±0.16, respectively, in Group C (all p=NS). Fig 6 shows examples of the immunohistochemistry study with factor VIII-related antigen in the ischemic region in each group; the number of vessels stained is increased in Group A compared with Groups B and C. In the ischemic region, the vascular densities in Groups A, B and C were 234±11, 162±14 and 149±18 /mm 2 , respectively (p<0.01, Group A vs Groups B and C, p=NS Groups B vs C), and in the non-ischemic region they were 118±6, 108±6 and 116±9 /mm 2 , respectively (p=NS among the 3 groups) (Fig 7) . 
Immunohistochemical Study
Discussion
The present study demonstrated that intramyocardial application of the continuous release-form, but not the freeform, of bFGF enhances collateral circulation development to the infarcted myocardium in dogs with a coronary occlusion. Our findings also support the hypotheses that collateral development would be directed to the area where bFGF was applied, and that neither collateral development nor angiogenic response would be observed in the non-ischemic area.
Slow-Release of bFGF
The present results clearly indicate the therapeutic efficacy of the gelatin-microsphere incorporating bFGF in the myocardial ischemia. Harada et al 5 demonstrated that the sustained release of bFGF was effective in improving myocardial function in chronically ischemic hearts. However, their bFGF carrier was an alginate microsphere containing heparin-sepharose beads. 13 The release of heparin-immobilized bFGF is mainly achieved through heparinase cleavage of heparin, which is reduced by incorporation into the calcium-crosslinked alginate microsphere. Because the alginate is a poorly biodegradable polysaccharide and erosion of its microspheres is mainly through natural leaching out of the calcium, it may be difficult to control the carrier degradation and the subsequent bFGF release. In addition, it is likely that the alginate microsphere, as well as nonbiodegradable sepharose beads, remains in the body. In our gelatin hydrogel system, bFGF is released as a result of microsphere degradation that can be controlled by changing the extent of gelatin crosslinking. 10 The microspheres are completely degraded in the body and so will not cause an inflammatory response.
Comparison With Previous Studies
bFGF has been administered by various routes in a variety of animal models. In a pioneering study, YanagisawaMiwa et al 2 injected the bFGF peptide into the coronary circulation 30 min and 6 h after acute coronary occlusion, and the ejection fraction, infarct size, and capillary density in the peripheral zone of the infarct were evaluated 1 week later. All these parameters were improved by the treatment. Because collateral development is a slow process, it was questioned how a reduction in the size of the infarct was achieved. However, Horrigan et al have recently demonstrated that myocardial salvage occurs independently of neovascularization after administration of bFGF. 14 Subsequently, many studies have shown an increase of collateral blood flow to the ischemic area using an intracoronary, 3, 4 intravenous, 6,8 intrapericardial 7 or intramyocardial 5 route of administration of bFGF. Of these studies, that There is a significant increase in Group A in the ischemic region compared with Groups B and C (*p<0.01, Group A vs Groups B and C). However, there is no difference among the groups in the nonischemic region.
of Harada et al is particularly interesting. 5 They showed that periadventitial administration of a slow-release bFGF in a porcine model of gradual coronary occlusion improved coronary collateral flow reserve in the potential ischemic area during rapid pacing. 5 Although they showed an increase in collateral development, the relation of the site of the bFGF-containing beads to the location of the angiogenesis remained unclear, whereas the present study has clearly shown that the effect of implanted bFGF-impregnated AGHM is local and neovascularization occurs toward the depot. In the present study, there was no increase in angiogenesis in the normal region, which is in agreement with earlier studies, and although the mechanisms responsible for upregulation of the FGF receptors are not fully understood, this phenomenon is, at least in part, explained by the absence of FGF receptors in normal cardiac tissue.
Clinical Implications
Several clinical studies of bFGF treatment for patients with coronary artery disease are ongoing. Sellke et al 15 have investigated the effect of local perivascular delivery of bFGF-impregnated heparin-alginate beads on collateral development in 8 patients who had viable but underperfused myocardial territory not amenable to bypass grafting. Interim analysis demonstrated the safety and technical feasibility of therapeutic angiogenesis with bFGF delivered by heparin-alginate slow-release devices. It appears likely that our newly developed bFGF-impregnated AGHM would also be effective in patients with coronary artery disease who were not indicated for balloon angioplasty or bypass grafting surgery.
Study Limitations
First, although we implanted the bFGF microspheres into the subepicardium distal to the LAD occlusion site, the application to another location (eg, border zone between the LAD and LCX) may have provided more efficient collateral development. Second, the range of bFGF concentrations necessary for a detectable effect was not determined, and the timing of bFGF administration was fixed to 2 weeks after acute coronary occlusion because of the complicated and time consuming nature of the experimental model. Third, the change in regional wall motion in the ischemic area was not evaluated systematically. In the dogs undergoing repeat left ventriculography, LVEF and LVEDP before and after the treatment were evaluated and neither of them changed significantly after the treatment. The wall motion in the left ventricular anterior segment (ie, the infarcted region) did not change after the treatment, which may have been because of an insufficient blood supply or a completely infarcted endocardial layer of the myocardium at risk. 16 Another possibilty is that the 2-week period after treatment is too short to allow the ischemic myocardium to recover contractility. Fourth, for the estimation of myocardial blood flow reserve, we used intravenous adenosine, which decreased aortic pressure and increased heart rate. Although each of the change induced by adenosine did not differ among the 3 groups, flow reserve might have been underestimated. Finally, we did not measure the local concentration of bFGF and therefore could not demonstrate a time-dependent release of bFGF in dogs treated with AGHM-bFGF. Measurement of the bFGF concentration in the myocardial interstitial fluid is required in a further study.
